A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough
Author:
Funder
Merck Sharp and Dohme
Merck
Meso Scale Diagnostics
Publisher
Elsevier BV
Subject
General Medicine,Immunology and Allergy
Reference37 articles.
1. Classification of cough as a symptom in adults and management algorithms: CHEST Guideline and Expert Panel Report;Irwin;Chest,2018
2. Risk factors for chronic cough among 14,669 individuals from the general population;Çolak;Chest,2017
3. Prevalence of chronic cough, patient characteristics and health outcomes among UK adults [ERS abstract];Mcgarvey;Eur Respir J,2019
4. Prevalence and burden of chronic cough in the United States;Meltzer;J Allergy Clin Immunol Pract,2021
5. Frequency of persistent cough and trends in seeking medical care and treatment-results of an internet survey;Fujimura;Allergol Int,2012
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cough medicines for children- time for a reality check;Paediatric Respiratory Reviews;2023-12
2. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough;JAMA;2023-10-10
3. Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis;eClinicalMedicine;2023-08
4. Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials;European Respiratory Review;2023-05-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3